[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Chiappino G: [Mesothelioma: the aetiological role of ultrathin fibres and repercussions on prevention and medical legal evaluation]. Med Lav; 2005 Jan-Feb;96(1):3-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mesothelioma has until now been considered to be a manifestation, occurring in the pleura and/or peritoneum, of the carcinogenic action of the total burden of inhaled asbestos fibres, in the same way as lung cancer.
  • Because of the pathogenic potential of very low exposure levels, the fact that the onset of the neoplasm always occurs in the parietal pleura, and the absence of any synergism with smoking, which is typical in the case of carcinoma, it was suspected that aetiopathogenetic differences existed but the reasons for such differences still could not be explained.
  • Only fibres of this class of size can cross the pulmonary-pleural barrier and are, therefore, the causal agent of mesothelioma and other benign pleural manifestations (plaques).
  • Moreover the ultrathin fibres that translocate from the lung to the pleura are not distributed casually on the parietal and visceral surfaces but move over the surfaces, to concentrate around the lymphatic reabsorption stomata situated on the parietal pleura.
  • The concentration of ultrathin fibres in punctiform areas of the parietal pleura and the extremely long biopersistence of the amphiboles now finally explain how very low exposures can cause mesothelioma in susceptible subjects and why the neoplasm always occurs on the parietal pleura.
  • CONCLUSIONS: In medical-legal assessments of cases of mesothelioma the etiological importance of the ultrathin fraction of fibres means that any assumption of the disease being avoidable must be discarded, at least up to the second half of the 1980s because until then this class of fibres, which today must be considered as the true causal agent of the neoplasm, was not visible under the optical microscope, nor could such fibres be measured or eliminated from the atmosphere of working environments.
  • [MeSH-major] Mesothelioma / etiology. Mesothelioma / prevention & control. Pleural Neoplasms / etiology. Pleural Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Lav. 2005 May-Jun;96(3):262; author reply 264-6 [16273846.001]
  • [CommentIn] Med Lav. 2005 May-Jun;96(3):263-4; author reply 264-6 [16273847.001]
  • (PMID = 15847104.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Mineral Fibers; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  •  go-up   go-down


2. Spanu A, Ginesu F, Pirina P, Solinas ME, Schillaci O, Farris A, Chessa F, Madeddu G, Marongiu P, Falchi A, Nuvoli S, Madeddu G: The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions. Int J Oncol; 2003 Mar;22(3):639-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the usefulness of 99mTc-tetrofosmin (TF) SPECT in the detection of intrathoracic malignant lesions, we studied 304 patients, 261 with malignant and 43 with benign lesions; 196 of the former had non-treated primary tumors, 193 lung cancer (LC) and 3 mesotheliomas, 11 had LC recurrences and 54 had metastases from different kinds of tumors.
  • Moreover, SPECT was concordant with CT in correctly evaluating the response to chemotherapy or surgery in all monitorized primary tumors cases, except in one in whom only SPECT detected residual tumor.
  • The semiquantitative analysis added useful information in differentiating malignant from benign lesions and in monitoring the response to chemo-therapy.
  • TF SPECT appears a highly accurate diagnostic method in the detection of intrathoracic malignant lesions, in lungs and pleura, as well as in NSCLC mediastinal lymph node staging and in monitoring treatment effectiveness, playing a complementary role to CT in selected cases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / surgery. Combined Modality Therapy. False Negative Reactions. False Positive Reactions. Female. Humans. Lung Diseases / radiography. Lung Diseases / radionuclide imaging. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Mesothelioma / drug therapy. Mesothelioma / pathology. Mesothelioma / radiography. Mesothelioma / radionuclide imaging. Mesothelioma / surgery. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm, Residual. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Pleural Neoplasms / surgery. Predictive Value of Tests. Sensitivity and Specificity. Tomography, X-Ray Computed. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12579319.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


3. Edwards JG, McLaren J, Jones JL, Waller DA, O'Byrne KJ: Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer; 2003 May 19;88(10):1553-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.
  • Matrix metalloproteinases (MMPs), in particular the gelatinases (MMP-2 and -9), play a significant role in tumour invasion and angiogenesis.
  • The expression and activities of MMPs have not been characterised in malignant mesothelioma (MM) tumour samples.
  • In a prospective study, gelatinase activity was evaluated in homogenised supernatants of snap frozen MM (n=35), inflamed pleura (IP, n=12) and uninflammed pleura (UP, n=14) tissue specimens by semiquantitative gelatin zymography.
  • Matrix metalloproteinases, and in particular MMP-2, the most abundant gelatinase, may play an important role in MM tumour growth and metastasis.
  • Agents that reduce MMP synthesis and/or activity may have a role to play in the management of MM.
  • [MeSH-minor] Adult. Aged. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Prognosis. Prospective Studies. Survival

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2009-13 [10928143.001]
  • [Cites] Invasion Metastasis. 1997;17(3):158-68 [9702942.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4629-37 [10969817.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1215-21 [10971431.001]
  • [Cites] Oncology. 2000 Aug;59(2):139-44 [10971173.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):169-77 [10996419.001]
  • [Cites] Br J Cancer. 2000 Nov;83(9):1147-53 [11027427.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):638-43 [11267973.001]
  • [Cites] Thorax. 2001 Jul;56(7):561-6 [11413356.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):291-8 [11531282.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):863-8 [11556838.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Dec;20(6):1117-21 [11717014.001]
  • [Cites] Lung Cancer. 2001 Dec;34 Suppl 2:S83-9 [11720747.001]
  • [Cites] FEBS Lett. 2001 Nov 23;508(3):365-8 [11728453.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):189-94 [11743663.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):24-9 [11869009.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1466-75 [11920503.001]
  • [Cites] Hepatology. 2002 May;35(5):1117-24 [11981761.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1864-70 [12085177.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1876-83 [12085179.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9 [2072706.001]
  • [Cites] Clin Exp Metastasis. 1993 Mar;11(2):183-9 [8444010.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 7;85(7):574-8 [8384265.001]
  • [Cites] Breast Cancer Res Treat. 1994 Jan;29(1):109-16 [7517221.001]
  • [Cites] Br J Urol. 1994 Dec;74(6):762-6 [7530131.001]
  • [Cites] Invasion Metastasis. 1994-1995;14(1-6):246-58 [7657517.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Int J Cancer. 1995 Oct 20;64(5):355-9 [7591310.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):190-6 [8548762.001]
  • [Cites] Chest. 1996 Mar;109(3 Suppl):21S-22S [8598137.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):316-24 [8658215.001]
  • [Cites] J Pathol. 1996 Apr;178(4):369-78 [8691313.001]
  • [Cites] Prostaglandins. 1996 Jan;51(1):1-17 [8900440.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Jul;156(1):240-7 [9230755.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):556-64 [9259391.001]
  • [Cites] J Pathol. 1997 Jun;182(2):211-6 [9274533.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Nov;17(5):583-91 [9374109.001]
  • [Cites] Chest. 1998 Jan;113(1 Suppl):61S-65S [9438692.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] J Pathol. 1997 Dec;183(4):377-9 [9496252.001]
  • [Cites] Chest. 1998 Mar;113(3):723-31 [9515850.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(6):291-6 [9692834.001]
  • [Cites] Clin Exp Metastasis. 1999 Jun;17(4):315-23 [10545018.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2349-55 [10873086.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1258-68 [10882864.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2726-34 [10914717.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Nov;30(11):1195-202 [9839445.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Mar;20(3):458-64 [10030844.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1231-5 [10096553.001]
  • [Cites] Thorax. 1999 Feb;54(2):169-79 [10325924.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S56-60 [10357560.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:228-35 [10415734.001]
  • [Cites] Chest. 1999 Aug;116(2):504-20 [10453882.001]
  • [Cites] J Pathol. 1999 Sep;189(1):72-8 [10451491.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • (PMID = 12771921.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2377107
  •  go-up   go-down


Advertisement
4. Veronesi G, Spaggiari L, Mazzarol G, De Pas M, Leo F, Solli P, Pastorino U: Huge malignant localized fibrous tumor of the pleura. J Cardiovasc Surg (Torino); 2000 Oct;41(5):781-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge malignant localized fibrous tumor of the pleura.
  • Localized fibrous tumor is an unfrequent mesenchymal neoplasm.
  • The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting.
  • We report a case of a giant right intrathoracic mass whose preoperative diagnosis, from an open biopsy, was consistent with sarcoma and, in a second review, with fibrous tumor of the pleura without any indication about malignancy.
  • Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
  • [MeSH-major] Fibroma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pneumonectomy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149649.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement